What is a realistic time to achieve the major clinical and commercial milestones?
Angioblast is in the process of finalizing GMP production of MPCs for allogeneic clinical trials, and initiated an autologous human trial for victims of a heart attack, which should be complete in the first quarter of 2007. Angioblast also expects to file and gain approval of an Investigational New Drug (IND) application for clinical trials using allogeneic MPCs for cardiovascular conditions by the end of 2006.